U.S. Markets closed
  • S&P 500

    +41.45 (+0.95%)
  • Dow 30

    +338.48 (+1.00%)
  • Nasdaq

    +150.45 (+1.02%)
  • Russell 2000

    +32.38 (+1.48%)
  • Crude Oil

    -0.05 (-0.07%)
  • Gold

    -9.80 (-0.55%)
  • Silver

    +0.46 (+2.05%)

    -0.0034 (-0.2924%)
  • 10-Yr Bond

    +0.0120 (+0.91%)
  • Vix

    -3.49 (-14.33%)

    -0.0045 (-0.3282%)

    +0.5600 (+0.5127%)

    -2,358.95 (-5.27%)
  • CMC Crypto 200

    +49.07 (+4.72%)
  • FTSE 100

    +102.39 (+1.47%)
  • Nikkei 225

    -200.31 (-0.67%)

CORRECTED-UPDATE 3-Labcorp sees rise in COVID-19 testing as Delta variant spreads (July 29)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Corrects company name to Labcorp, from LabCorp, in headline and throughout the copy in July 29 story. A previous version of the story had the same error.)

July 29 (Reuters) - Laboratory Corp of America Holdings said on Thursday it has seen a rise in COVID-19 testing in July with the spread of the more contagious Delta variant across the United States.

The variant, first identified in India, is now the dominant one worldwide and has led to a spike in infection rates that has stoked widespread concerns over a economic recovery.

Labcorp said it saw a sequential decline in COVID-19 testing each month through the year with tests performed in month of June falling below the second-quarter average of 54,000 PCR tests per day.

"July was the first month, frankly, that we've seen the level of COVID testing higher than the prior month," said Glenn Eisenberg, Labcorp's Chief Financial Officer.

The comments echo those of Quest Diagnostics, which also saw demand for COVID-19 testing increase since the end of June.

Labcorp said it now believes reduction in testing would be lesser than what it had previously expected through the year.

The company's second quarter results saw it join other COVID-19 testing companies such as Quest Diagnostics and Abbott Labs in signaling a recovery in their mainstay businesses as mass inoculations prompted people to return to non-urgent care in the United States.

Labcorp raised its 2021 adjusted profit between $21.50 and $25 per share from previous outlook of $20 to $24 per share on the back of the recovery, especially in its diagnostics unit which offers services such as genetic, pathology and drug monitoring tests.

The company said for the first time since the pandemic, its non-COVID-19 testing volumes rose in June compared to 2019 and expects continued growth through the year.

Excluding items, it earned $6.13 per share, beating analyst estimates of $5.53 per share, according to Refinitiv IBES data.

Revenue of $3.84 billion also topped estimates of $3.61 billion. (Reporting by Amruta Khandekar in Bengaluru; Editing by Shailesh Kuber)